Lexaria Eyes Up to $60B Oral GLP-1 Pill Market with DehydraTECH
Lexaria notes 600,000 Wegovy pill prescriptions were written in its first two months and projects oral formats will drive 51% of Wegovy revenue growth through 2031 with semaglutide peak sales of $15.9 billion in 2030. Its DehydraTECH platform enhances bio-absorption for semaglutide, tirzepatide and liraglutide.
1. GLP-1 Pill Market Expansion
The FDA approved the first GLP-1 weight-loss pill, Wegovy, in December 2025 and launched it in January 2026, leading to 600,000 prescriptions written in the first two months. This rapid uptake underscores that oral GLP-1 formulations are growing faster than injectable counterparts.
2. DehydraTECH Efficacy Across GLP-1 Drugs
Lexaria’s patented DehydraTECH platform has demonstrated increased bio-absorption and reduced side effects for semaglutide, tirzepatide and liraglutide. The company’s 2026 R&D program will explore applications to next-generation GLP-1 candidates such as retatrutide and amycretin, and discussions with pharmaceutical partners are underway.
3. Revenue Forecasts and Market Opportunity
Industry forecasts project oral GLP-1 pills to drive 51% of Wegovy revenue growth through 2031, with semaglutide peak sales estimated at $15.9 billion in 2030. Broader GLP-1 sales are projected between $101 billion and $180 billion by the mid-2030s, implying an oral segment valued at $17 billion to $60 billion, a market Lexaria aims to capture.